Pay in 4 interest-free payments of $29.75 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Activating mutations in leucine-rich repeat kinase 2 (LRRK2) are present in a subset of Parkinson's disease (PD) patients and may represent an attractive therapeutic target
TAK-220 inhibits R5 HIV-1 (JR-FL) envelope-mediated membrane fusion
InChiKey: OZBDFBJXRJWNAV-UHFFFAOYSA-N
Solubility: DMSO : ≥ 50 mg/mL (132
No significant changes in body weights
NNC 26-9100 /p300-IN-5 Activating mutations in leucine-rich repeatProduct information CAS Number: 199522 35 5 Molecular Weight: 556. 35 Formula: C22H25BrCl2N6S Chemical Name: (Z) N {3 [(5 bromopyridin 2 yl)[(3,4 dichlorophenyl)methyl]amino]propyl} N' [3 (1H imidazol 5 yl)propyl]carbamimidothioic acid Smiles: S C( NCCCN(CC1C=CC(Cl)=C(Cl)C=1)C1C=CC(Br)=CN=1)=N\CCCC1=CN=CN1 InChiKey: UREJDUPKGMFJRU UHFFFAOYSA N InChi: InChI=1S C22H25BrCl2N6S c23 17 5 7 21(29 12 17)31(14 16 4 6 19(24)20(25)11 16)10 2 9 28 22(32)27 8 1 3
US$ 475.00
US$ 1017.50
US$ 4116.00
US$ 875.00
US$ 2381.50
US$ 149.47
US$ 170.50
US$ 359.50